Affiliation: Imperial College
- Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)Emma Morris
Department of Haematology, University College London Hospitals, 98 Chenies Mews, London W1E6HX, United Kingdom
Transfus Apher Sci 32:73-83. 2005..Patients with relapsed LG-NHL and CLL achieve excellent PFS with extremely low TRM and GVHD, even when matched family donors are unavailable...
- Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris
Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
Blood 102:404-6. 2003..Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P =.005), and median absolute CD4 counts higher than 200 x 106/L were delayed until 9 months after transplantation...
- Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphomaEmma Morris
Department of Haematology, Royal Free and University College Hospitals Medical School, 98 Chenies Mews, London WC1E 6HX, United Kingdom
Blood 104:3865-71. 2004..Patients who experienced relapses of LG-NHL and chronic lymphocytic leukemia (CLL) achieved excellent PFS with extremely low TRM and GVHD, even when matched related donors were unavailable...
- Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphomaEmma C Morris
Department of Haematology, Royal Free and University College London Hospitals Medical School, London WC1E 6HX, UK
Best Pract Res Clin Haematol 18:129-42. 2005..Here we will discuss the rationale behind reduced intensity transplantation (RIT), the development of the regimens currently adopted in clinical practice and review the published literature on RIT for indolent NHL...
- Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantationGuillermo Orti
Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
Transplantation 88:1312-8. 2009..The drawback of DLI is the risk of graft-versus-host disease (GVHD). In this phase I study, we examined the potential of highly extensive CD8 depletion of DLI as a means of improving its safety profile...
- HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioningAdam J Mead
Department of Haematology, University College London UCL Medical School, London, United Kingdom
Blood 115:5147-53. 2010..44). Mismatch occurred at the antigenic level in 40 cases. The outcome in these cases did not differ significantly from the rest of the cohort. We conclude that RIT using HLA-mismatched grafts is a viable option using FMC conditioning...
- Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesKarl S Peggs
Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
Blood 103:1548-56. 2004....
- T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphomaKirsty J Thomson
Department of Haematology, University College Hospital, London, UK
J Clin Oncol 28:3695-700. 2010..Thus, reduced-intensity conditioning regimens are being explored...
- Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activityKarl S Peggs
Department of Haematology, University College London Hospitals, London, United Kingdom
Biol Blood Marrow Transplant 9:257-65. 2003..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
- Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs
Department of Haematology, Royal Free and University College London, UK
Lancet 365:1934-41. 2005..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
- Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphomaJonathan R Lambert
Department of Haematology, University College London Cancer Institute, London, UK
Blood 115:2763-8. 2010....
- Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimenKarl S Peggs
Blood 99:4642-3; author reply 4643-4. 2002
- Reversal of severe cholestasis caused by chronic graft-versus-host disease with the MARS liver-support deviceSambit Sen
Transplantation 75:1766-7. 2003
- A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protectionEmma C Morris
Department of Immunology, Imperial College, Du Cane Road, London W12 0NN, United Kingdom
Proc Natl Acad Sci U S A 102:7934-9. 2005..The data demonstrate in vivo synergy between T cell antigen receptor-transduced CD4(+) and CD8(+) T cells specific for the same epitope resulting in long-term tumor protection...
- Monoclonal T-cell receptors: new reagents for cancer therapyHans J Stauss
Department of Immunology and Molecular Pathology, University College London, Hampstead Campus, Royal Free Hospital, London, UK
Mol Ther 15:1744-50. 2007..Both, expression of only the introduced TCR chains and the production of naïve T cells may be possible in the future by TCR gene transfer into stem cells...
- Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemiaEmma C Morris
Department of Haematology, Great Ormond Street Hospital for Children, London, UK
Br J Haematol 120:787-9. 2003..02) and time from diagnosis to second CNS relapse (longer time was better, P = 0.004). Prognosis after second CNS relapse is extremely poor, and palliative therapy is appropriate...